| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.24▼ | 1.24▼ | 1.24▼ | 1.20▼ | 1.49▼ |
| MA10 | 1.25▼ | 1.25▼ | 1.25▼ | 1.28▼ | 1.37▼ |
| MA20 | 1.32▼ | 1.36▼ | 1.37▼ | 1.47▼ | 1.28▼ |
| MA50 | 1.48▼ | 1.54▼ | 1.58▼ | 1.37▼ | 1.34▼ |
| MA100 | 1.62▼ | 1.57▼ | 1.45▼ | 1.30▼ | 1.23▼ |
| MA200 | 1.46▼ | 1.37▼ | 1.34▼ | 1.42▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.000▲ | -0.001▼ | -0.003▼ | -0.054▼ | 0.001▲ |
| RSI | 34.649▼ | 35.088▼ | 34.947▼ | 33.131▼ | 44.881▼ |
| STOCH | 33.642 | 33.025 | 26.252 | 7.617▼ | 51.327 |
| WILL %R | -85.185▼ | -86.667▼ | -88.571▼ | -100.000▼ | -87.611▼ |
| CCI | -81.481 | -80.879 | -77.778 | -98.307 | -49.930 |
|
Sunday, March 22, 2026 10:00 PM
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (“Estrella” or ...
|
|
Sunday, March 22, 2026 05:00 PM
Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS ® T-cell therapies to treat cancer ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 15/05/26 | 1.22 | 1.22 | 1.11 | 1.11 | 27,997 |
| 14/05/26 | 1.27 | 1.27 | 1.15 | 1.205 | 40,363 |
| 13/05/26 | 1.2694 | 1.27 | 1.1301 | 1.20 | 24,666 |
| 12/05/26 | 1.22 | 1.2301 | 1.21 | 1.21 | 8,806 |
| 11/05/26 | 1.26 | 1.28 | 1.22 | 1.26 | 18,395 |
| 08/05/26 | 1.25 | 1.2672 | 1.205 | 1.26 | 42,344 |
| 07/05/26 | 1.335 | 1.335 | 1.25 | 1.27 | 17,775 |
| 06/05/26 | 1.31 | 1.4599 | 1.30 | 1.30 | 51,496 |
| 05/05/26 | 1.50 | 1.55 | 1.39 | 1.4065 | 18,805 |
| 04/05/26 | 1.57 | 1.60 | 1.44 | 1.53 | 19,392 |
|
|
||||
|
|
||||
|
|